Cobalt Capital Management Inc. Buys New Shares in Teva Pharmaceutical Industries Ltd. $TEVA

Cobalt Capital Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the fourth quarter, Holdings Channel reports. The institutional investor bought 118,201 shares of the company’s stock, valued at approximately $3,689,000. Teva Pharmaceutical Industries comprises 1.6% of Cobalt Capital Management Inc.’s holdings, making the stock its 16th biggest holding.

A number of other institutional investors also recently modified their holdings of the stock. Bamco Inc. NY lifted its position in shares of Teva Pharmaceutical Industries by 9.1% during the 4th quarter. Bamco Inc. NY now owns 120,000 shares of the company’s stock valued at $3,745,000 after acquiring an additional 10,000 shares during the period. Ardsley Advisory Partners LP lifted its position in shares of Teva Pharmaceutical Industries by 16.0% during the 4th quarter. Ardsley Advisory Partners LP now owns 580,000 shares of the company’s stock valued at $18,102,000 after acquiring an additional 80,000 shares during the period. Altshuler Shaham Ltd lifted its position in shares of Teva Pharmaceutical Industries by 2.4% during the 4th quarter. Altshuler Shaham Ltd now owns 8,494,121 shares of the company’s stock valued at $268,670,000 after acquiring an additional 196,697 shares during the period. ACT Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $718,000. Finally, DV Equities LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $69,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $32.59 on Thursday. The company has a fifty day moving average price of $33.46 and a 200-day moving average price of $32.17. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The firm has a market cap of $37.47 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 3.36 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a 1 year low of $14.99 and a 1 year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The company had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on TEVA. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Finally, Truist Financial boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Buying and Selling

In related news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. The trade was a 34.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the transaction, the executive vice president directly owned 63,647 shares in the company, valued at $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 465,931 shares of company stock worth $16,332,989 in the last ninety days. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.